These findings highlight the potential role of SGLT2 inhibitors in preventing hyperkalaemia following the initiation or up‐titration of other heart failure therapies, thereby enhancing the tolerability of ARNI and MRAs treatment.55, 57, 58. The gene discussed is SLC5A2; the disease is Hyperkalemia.